ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 573,37
-0,78%
Dow Jones
40 211,72
0,00%
DAX
18 487,72
-0,60%
Brent Oil
83,075
-1,50%
Bitcoin
63 992,44
-1,32%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Portola Pharmaceuticals Inc (PTLA)

  7. Portola Pharmaceuticals Inc (PTLA) Actualités

PTLA

Portola Pharmaceuticals (PTLA)

Portola Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PTLA
DateHeureSourceTitreSymboleSociété
23/02/201615h27Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:PTLAPortola Pharmaceuticals Inc
19/02/201614h00GlobeNewswire Inc.Portola Pharmaceuticals to Announce Fourth Quarter and Year-End 2015 Financial Results and Host Conference Call on Friday, Fe...NASDAQ:PTLAPortola Pharmaceuticals Inc
17/02/201623h42GlobeNewswire Inc.Portola Pharmaceuticals Announces Biologics License Application for Andexanet Alfa Accepted for Review by FDANASDAQ:PTLAPortola Pharmaceuticals Inc
12/02/201623h35Edgar (US Regulatory)Amended Annual Statement of Changes in Beneficial Ownership (5/a)NASDAQ:PTLAPortola Pharmaceuticals Inc
12/02/201615h27Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PTLAPortola Pharmaceuticals Inc
11/02/201620h24Edgar (US Regulatory)Schedule 13g
(sc 13g/a)		NASDAQ:PTLAPortola Pharmaceuticals Inc
10/02/201615h43Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:PTLAPortola Pharmaceuticals Inc
01/02/201622h04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PTLAPortola Pharmaceuticals Inc
01/02/201612h55GlobeNewswire Inc.Portola Pharmaceuticals Enters Into Licensing Agreements for Investigational Agent Andexanet Alfa in Japan Worth Up to $120 M...NASDAQ:PTLAPortola Pharmaceuticals Inc
29/01/201623h16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PTLAPortola Pharmaceuticals Inc
26/01/201619h31Edgar (US Regulatory)Annual Statement of Changes in Beneficial Ownership (5)NASDAQ:PTLAPortola Pharmaceuticals Inc
08/01/201614h00GlobeNewswire Inc.Portola Pharmaceuticals to Webcast Corporate Update on January 12, 2016NASDAQ:PTLAPortola Pharmaceuticals Inc
18/12/201514h00GlobeNewswire Inc.Portola Pharmaceuticals Completes BLA Submission to U.S. Food and Drug Administration for Andexanet AlfaNASDAQ:PTLAPortola Pharmaceuticals Inc
09/12/201512h08Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:PTLAPortola Pharmaceuticals Inc
05/12/201514h00GlobeNewswire Inc.Portola Pharmaceuticals Announces Andexanet Alfa and Cerdulatinib Data Presentations at the 2015 American Society of Hematolo...NASDAQ:PTLAPortola Pharmaceuticals Inc
04/12/201514h00GlobeNewswire Inc.Portola Announces Pricing of Public Offering of Common StockNASDAQ:PTLAPortola Pharmaceuticals Inc
03/12/201522h35GlobeNewswire Inc.Portola Pharmaceuticals Announces Proposed Offering of Common StockNASDAQ:PTLAPortola Pharmaceuticals Inc
12/11/201514h00GlobeNewswire Inc.Portola Pharmaceuticals to Host Analyst and Investor Day on November 19NASDAQ:PTLAPortola Pharmaceuticals Inc
11/11/201516h45GlobeNewswire Inc.The New England Journal of Medicine Publishes Results of Portola Pharmaceuticals’ Phase 3 ANNEXA Studies of Andexanet AlfaNASDAQ:PTLAPortola Pharmaceuticals Inc
09/11/201523h11Edgar (US Regulatory)Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)NASDAQ:PTLAPortola Pharmaceuticals Inc
09/11/201523h07Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PTLAPortola Pharmaceuticals Inc
09/11/201522h05GlobeNewswire Inc.Portola Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate UpdateNASDAQ:PTLAPortola Pharmaceuticals Inc
06/11/201514h00GlobeNewswire Inc.Portola Pharmaceuticals Announces Phase 3 ANNEXA™-R Part 2 Study Results to be Presented at American Heart Association Scie...NASDAQ:PTLAPortola Pharmaceuticals Inc
04/11/201514h00GlobeNewswire Inc.Portola Pharmaceuticals to Present at Credit Suisse 24th Annual Healthcare ConferenceNASDAQ:PTLAPortola Pharmaceuticals Inc
02/11/201514h00GlobeNewswire Inc.Portola Pharmaceuticals to Announce Third Quarter 2015 Financial Results and Host Conference Call on Monday, November 9NASDAQ:PTLAPortola Pharmaceuticals Inc
30/10/201513h00GlobeNewswire Inc.Portola Pharmaceuticals Completes Enrollment in Pivotal Phase 3 APEX Study of Betrixaban for Prevention of Blood Clots in Ac...NASDAQ:PTLAPortola Pharmaceuticals Inc
22/10/201515h02The Motley Fool3 Healthcare Trends Johnson & Johnson Told Us About This Earnings SeasonNASDAQ:PTLAPortola Pharmaceuticals Inc
18/10/201514h02The Motley Fool3 Biotech Long Shots That Could Be Worth Betting OnNASDAQ:PTLAPortola Pharmaceuticals Inc
13/10/201514h00GlobeNewswire Inc.Portola Pharmaceuticals Announces FDA Grants Fast Track Designation to Betrixaban for Prevention of Blood Clots in Acute Medi...NASDAQ:PTLAPortola Pharmaceuticals Inc
25/09/201519h02Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:PTLAPortola Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:PTLA

Dernières Valeurs Consultées

NASDAQ
GOOGL
Alphabet
EU
MC
Lvmh Moet Hennessy Louis...
SPI
SP500
S&P 500
NYSE
MRK
Merck
NYSE
MCD
McDonalds
EU
ACA
Credit Agricole
NASDAQ
MSFT
Microsoft
EU
PX1
CAC 40
EU
LR
Legrand
USI
USTECH100
US Tech 100
FTSE
UKX
FTSE 100
EU
AF
Air FranceKLM
EU
VIV
Vivendi
NYSE
NKE
Nike
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés